Publications
-
Quantitative characterization of immune cells by measuring cellular signal transduction pathway activity
-
Quantification of PI3K/AKT/mTOR Pathway Inhibition is Predictive of Biological Response
-
Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma
-
Increased PI3K pathway activity is associated with recurrent breast cancer in patients with low-intermediate 21-gene recurrence score
-
Identifying mutation-independent signaling pathway activation in molecular subtypes of triple negative breast cancers
-
Determining tumor-driving cell signaling pathways in breast cancer: Support for targeted therapy selection
-
Pathway profiling for prediction of response to neoadjuvant letrozole therapy in ER positive postmenopausal breast cancer; gaining new insights for targeted treatment
-
Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol
-
A novel Laboratory Developed Test for identification of key tumor driving cell signaling pathways in breast cancer: ER, AR, PI3K, MAPK, Hedgehog, TGFβ and Notch
-
Targeted RNA expression-based signaling pathway analysis of epigenetic subtypes of triple negative breast cancers identifies mutation-independent pathway activation
-
Quantitative cell signalling activity profiling of solid tumors to support personalized treatment in the FINPROVE basket trial; presentation of skin tumor data
-
Myeloid-derived suppressor cells and tolerogenic dendritic cells are distinctively induced by PI3K and Wnt signaling pathways
-
Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen-receptor pathway inhibitors
-
Non-muscle Invasive Bladder Cancer Molecular Subtypes Predict Differential Response to Intravesical Bacillus Calmette-Guérin
-
Racial disparities in ER signaling pathway activity in breast cancer patients undergoing short-course preoperative hormone therapy: a window of opportunity trial
-
Improved diagnosis of inflammatory bowel disease and prediction and monitoring of response to anti-TNF alpha treatment based on measurement of signal transduction pathway activity
-
Support for targeted therapy selection in triple-negative breast cancer patients using aberrant signal transduction pathway activity profiles
-
Signal transduction pathway activity of TGF-β and Hedgehog as possible response predictors to checkpoint inhibition in patients with advanced melanoma; a retrospective cohort study
-
Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low-grade ovarian carcinoma
-
The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis
-
The use of ribociclib/letrozole combination as an alternative for neoadjuvant chemotherapy in selected patients with early luminal breast cancer
-
High Sonic Hedgehog (HH) signalling activity, low androgen receptor activity and clonal evolution are associated with resistance to androgen receptor axis inhibitors in patients with metastatic prostate cancer
-
Measurement of activity of developmental signal transduction pathways to quantify stem cell pluripotency and phenotypically characterize differentiated cells
-
Identification of signal transduction pathway activity with a potential clinical implication in high grade serous ovarian carcinoma
-
The relevance of estrogen driven tumor growth within molecular subgroups of endometrial cancer
-
FOXO transcriptional activity is associated with response to chemoradiation in EAC
-
Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium
-
Characterization of Immunoactive and Immunotolerant CD4+ T Cells in Breast Cancer by Measuring Activity of Signaling Pathways That Determine Immune Cell Function
-
Cyclic activity of signal transduction pathways in fimbrial epithelium of the human fallopian tube
-
Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma
-
Androgen receptor pathway activity assay for sepsis diagnosis and prediction of favorable prognosis
-
Survival is Related to Estrogen Signal Transduction Pathway Activity in Postmenopausal Women Diagnosed with High-Grade Serous Ovarian Carcinoma
-
Measuring host immune response status by simultaneous quantitative measurement of activity of signal transduction pathways that coordinate functional activity of immune cells from innate and adaptive immune system
-
Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1
-
Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade
-
Heterogeneity in Signaling Pathway Activity within Primary and Between Primary and Metastatic Breast Cancer
-
RNA Based approaches to profile oncogenic pathways from low quantity samples to drive precision oncology strategies
-
A molecular test for quantifying functional Notch signaling pathway activity in human cancer
-
Measurement of cellular immune response to viral infection and vaccination
-
Signal transduction pathway activity in high-grade, serous ovarian carcinoma reveals a more favorable prognosis in tumors with low PI3K and high NF-КB pathway activity: A novel approach to a long-standing enigma
-
Oestrogen receptor pathway activity is associated with outcome in endometrial cancer
-
ER and PI3K pathway activity in primary ER positive breast cancer is associated with progression-freesurvival of metastatic patients under first-line tamoxifen
-
Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients
-
Estrogen receptor pathway activity score to predict clinical response or resistance to neo-adjuvant endocrine therapy in primary breast cancer
-
Quantitative measurement of functional activity of the PI3K signaling pathway in Cancer
-
Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types
-
Assessment of functional phosphatidylinositol 3-kinase pathway activity in cancer tissue using forkhead box-o target gene expression in a knowledge-based computational model
-
Complete sequence-based pathway analysis by differential on-chip DNA and RNA extraction from a single cell
-
Knowledge-based computational models
-
Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways
-
Evaluation of the activity of key actionable oncogenic driving pathways in triple negative breast cancer using OncoSignal™; a novel molecular assay based on transcriptional profile analysis
-
Breast cancer IHC subtypes display heterogeneous and independent targetable signaling pathway activity profiles
-
Differential Pathway Analyses of BCG Treated Bladder Cancer Using Philips OncoSignal: A Pilot Study
-
A robust rapid mRNA based test to profile simultaneously ER, AR, PI3K and MAPK functional signaling pathway activity for precision oncology
-
Quantitative assessment of functional activity of multiple signaling pathways in recurrent breast cancer with low-intermediate 21 gene recurrence score
-
Development of quantitative multi platform tests for easy readout of AR, ER, PI3K and MAPK pathway activity to unravel-pathophysiology across cancer and tissue types
-
First results of the EIT PACMAN Study: OncoSignal pathway analysis to identify clinically actionable signal transduction pathway activity in a variety of cancer types
-
The MAPK pathway is variably active across breast cancer subtypes and increased activity may be associated with hormonal therapy resistance
-
Androgen receptor pathway activity and the ratio between androgen and estrogen receptor pathway activity in breast cancer subtypes
-
The MAPK pathway is variably active across breast cancer subtypes, and increased activity may be associated with hormonal therapy resistance
-
A test to quantify Notch pathway activity in t cell acute lymphoblastic leukemia patients
-
Fulvestrant resistance in an MCF-7 model for breast cancer is associated with complete loss of ER pathway activity and gain of MAPK-AP1 pathway activity
-
Quantitative measurements of functional activity of the TGFβ and MAPK-AP1 pathways in colon cancer provides information on their role in cancer development and metastasis
-
Changes in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival (DFS) in ER positive breast cancer patients
-
Exploring candidate signal transduction pathways for targeted therapy in esophageal cancer
-
Signal transduction pathway activity in normal fallopian tube epithelium and high-grade serous carcinoma
-
Measuring functional PI3K and NFkB pathway activity to distinguish between short-term and long-term disease-free survivors of high grade serous ovarian cancer
-
Heterogeneity in signaling pathway activity within primary breast cancer and between primary and metastases
-
Measuring the activity of multiple signal transduction pathways in cancer using RNA sequencing on cells and FFPE tissue
-
ER pathway activity score as a predictive biomarker to improve stratification for neo-adjuvant endocrine therapy
-
Quantitative measurement of multiple signal transduction pathway activities in cell and tissue culture, including cancer, fibroblasts, and immune cell types: a new way forward to standardization of cell culture experiments
-
Breast cancer induces a tolerogenic state of healthy activated CD4+ T-cells, characterized by reduced PI3K, NFκB, JAK-STAT, Notch, and increased TGFβ pathway activity
-
Elucidating the role of functional signal transduction pathway activity in sensitivity and response of triple negative breast cancer PDXs to PI3K inhibition
-
Does hormone expression by IHC predict ER pathway activity? An analysis in a metastatic breast cancer patient cohort
-
Assays for measurement of functional signal transduction pathway activity in any cell or tissue sample
-
Signal transduction pathway activity before and after neoadjuvant treatment in esophageal cancer
-
Estrogen receptor pathway activity in endometrial carcinomas and its relation to tumor grade and disease related mortality
-
Analysis of functional androgen receptor-pathway activity to predict response to androgen deprivation therapy in salivary duct carcinoma
-
Assessment of functional signal transduction pathway activity in patient-derived tumor xenografts to predict and evaluate therapy response
-
Assays for measurement of functional signal transduction pathway activityin any cell or tissue sample
-
Hedgehog signalling pathway activity in high-grade serous ovarian carcinoma
-
Robust measurement of signal transduction pathway activity in cancer using RNA sequencing on cells and FFPE tissue
-
Measuring functional signal transduction pathway activity on breast cancer tissue samples to determine intra-tumor heterogeneity and heterogeneity between primary and metastatic tumors
-
Determination of signal transduction pathway activity in patient-derived xenograft models in comparison with clinical patient tumor samples for a variety of human cancer types
-
Measuring functional PI3K pathway activity in cancer tissue using FOXO target gene expression in a knowledge-based computational model
-
Assessing functional androgen receptor (AR) pathway activity using a computational model
-
Oncogenic signal transduction pathway activity in glioblastoma and relation to therapy response
-
Analysis of active oncogenic signal transduction pathways in HGS ovarian cancer HH pathway activity associated with platin resistance
-
Elucidating pediatric brain tumor pathophysiology by assessing signal transduction pathway activation
-
Predicting first line tamoxifen response of recurrent ER+ breast cancer patients based on transcriptional activity of signaling pathways
-
Prognosis within different breast cancer subtypes using functional activity of signaling pathways
-
Assessing functional ER pathway activity using a computational pathway model
-
Identifying tumor driving signaling pathways using computational pathway models
-
Personalized cancer treatment selection using computational signaling pathway models